Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
Centauri Therapeutics, a UK-based immunotherapy company focused on the treatment of infectious diseases, has announced three senior appointments at once. 12 July 2022
Swiss clinical-stage biotech Vaccentis, which is developing patient-specific medicines, today announced the appointment of Martin Munte, a veteran leader in biotech and pharma. 12 July 2022
Privately-held German biotech Ariceum Therapeutics, which is focused on developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, has named Serge Sagodira its chief business officer. 7 July 2022
US development-stage mRNA-technology company Kernal Biologics today announced the completion of a $25 million Series A led by Hummingbird Ventures. 7 July 2022
Canadian clinical-stage biotech Zymeworks today announced that it is strengthening its senior leadership team with the appointment of Paul Moore, as chief scientific officer, reporting directly to the chief executive Officer. 27 June 2022
Just three months after Nutcracker Therapeutics’ announcement of receiving $167 million in Series C funding, three new leadership positions have been filled alongside the release of its oncology and disease-focused pipeline. 22 June 2022
Swiss antibody-drug conjugate specialist ADC Therapeutics announced today it has appointed industry veteran David Gilman to the new role of chief business and strategy officer, reporting to chief executive Ameet Mallik effective July 1. 13 June 2022
Biotech funder and incubator Flagship Pioneering and Tessera Therapeutics, a biotechnology company pioneering GENE WRITING technology backed by Flagship, today announced that Michael Severino has joined Tessera as chief executive. 3 June 2022
US biotech major Gilead Sciences has announced that Stacey Ma will join the company as executive vice president, pharmaceutical development and manufacturing, and will become a member of the company’s senior leadership team, reporting to chairman and chief executive, Daniel O’Day. 3 June 2022
Gene therapy company Opus Genetics, which is developing treatments for inherited retinal diseases, today announced the appointment of Jennifer Hunt as chief development officer. 11 May 2022
US start-up biotech MOMA Therapeutics, which is discovering the next generation of precision medicines by targeting molecular machines that underlie human disease, today announced the completion of a $150 million Series B financing. 10 May 2022
Swiss antibody-drug conjugate specialist ADC Therapeutics today announced that Chris Martin has stepped down as chief executive of the company. 9 May 2022
Enthera Pharmaceuticals, a privately-held Italian biotech developing biologics for selected autoimmune conditions based on the discovery of an apoptosis pathway, has named Aled Williams chief executive. 6 May 2022
Coming out of stealth since its founding in 2019, US biotech Dianthus Therapeutics today announced the completion of its $100 million Series A financing led by 5AM Ventures, Avidity Partners, and Fidelity Management & Research Company. 3 May 2022
US messenger RNA (mRNA) therapeutics and vaccines specialist Moderna has announced that Arpa Garay will join the firm as chief commercial officer (CCO), effective Monday, May 31, 2022. She 28 April 2022
Boston, USA-based biotech start-up Jnana Therapeutics today announced the appointment of Doug Pagán, as both chief financial and chief operating officer. 26 April 2022
Privately-held French biotech focused on providing immuno-therapeutics Biomunex Pharmaceuticals today announces the appointment of Dr Simon Plyte as chief scientific officer (CSO) and as a member of its scientific advisory board. 25 April 2022
Cancer-focused cell therapy company ImmPACT Bio USA today announced the appointment of Venkata Yepuri as chief operating officer. In this role, Mr Yepuri will oversee business operations across the company. 20 April 2022
Biotech funder and incubator Flagship Pioneering today announced that Michael Severino is joining the company as chief executive (CEO)-partner. 13 April 2022